Drug Trial Radar · NCT05498766
Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
Last checked: Nov 19, 2026Latest source record: Jun 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
702
Planned (sponsor's estimate)
Start
Jul 1, 2024
Primary completion
Jul 1, 2029
Study completion Nov 1, 2029
Sponsor
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- LinkDoc Technology (Beijing) Co. Ltd.
- First posted
- Aug 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-center, open-label, randomised controlled study. The purpose of this study is to evaluate the efficacy and safety of Huaier Granule versus SOX regimen in the postoperative adjuvant treatment of resectable stage II-III gastric cancer.
Conditions
- Gastric Cancer
Interventions
Huaier granuleDrug
Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.
OxaliplatinDrug
Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.
Tegafur, Gimeracil and Oteracil PotassiumDrug
Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3-year DFS rateTime frame: up to 36-months follow-up
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Wuhan Union Hospital
Wuhan, Hubei, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.